Free Delivery Over $100
|
|
|||
|
||||
OverviewTen years have elapsed since the publication in 1978 of Vol. 49 of the Handbook of Experimental Pharmacology [41], a toOO-page survey of the data then available on Ergot Alkaloids and Related Compounds. A booklet published in 1979 presented the in formation on one of these compounds, namely co-dergocrine (Hydergine@), as extracted from the Handbook and updated to take the latest developments into account [42]. Co-dergocrine had at the time been on the market for 30 years and had given rise to over 2000 papers, so that one might have felt justified in thinking that its scientific history had virtually come to an end. It has now become obvious that such a view would have been wide of the mark. Research on the pharmacology and clinical pharmacology of co-dergocrine has remained as active as ever. The resulting obsolescence of the 1979 booklet made necessary the preparation of the present version. Like its predecessor, it is intended as an inventory of findings and facts rather than a work dealing with their interpretation. Full Product DetailsAuthor: Claude WeilPublisher: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG Imprint: Springer-Verlag Berlin and Heidelberg GmbH & Co. K Edition: Softcover reprint of the original 1st ed. 1988 Dimensions: Width: 17.00cm , Height: 0.60cm , Length: 24.40cm Weight: 0.229kg ISBN: 9783642737046ISBN 10: 3642737048 Pages: 111 Publication Date: 23 December 2011 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: Manufactured on demand  We will order this item for you from a manufactured on demand supplier. Table of ContentsI. Introduction and Background Information.- II. Basic Pharmacologic Properties: Peripheral Effects on Neurotransmission.- 1. Actions at Adrenoceptors.- 2. Actions at Dopamine Receptors.- 3. Actions at Serotonin (5-HT) Receptors.- 4. Miscellaneous and Unspecific Effects.- III. Basic Pharmacologic Properties: Central Effects.- 1. Effects on Neurotransmission.- 2. Effects on Brain Enzymes and Metabolism.- 3. Effects on Cerebral Blood Flow.- 4. Other Effects.- 5. Conclusions.- IV. Effects of Co-Dergocrine on the Cardiovascular System.- V. Effects of Co-Dergocrine on Other Organs and Cells.- 1. Effects on the Uterus.- 2. Effects on the Kidney.- 3. Effects on Blood Platelets.- VI. The Clinical Pharmacology of Co-Dergocrine in Age-Related Cerebral Insufficiency.- 1. Cerebral Blood Flow (CBF).- 2. Clinical Rating Scales.- 3. Psychometric Tests.- 4. Electroencephalography.- VII. Co-Dergocrine in Various Cardiovascular and Cerebral Indications.- 1. Arterial Hypertension.- 2. Shock.- 3. Stroke.- 4. Inner-Ear Disorders.- 5. Tardive Dyskinesia.- VIII. Biopharmaceutical Aspects.- IX. Toxicologic Considerations.- References.ReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |
||||
